Synthesis of 2,3,4,7-tetrahydro-1H-azepines as privileged ligand scaffolds for the design of aspartic protease inhibitors via a ring-closing metathesis approach

Journal of Organometallic Chemistry

Volumn 691, Issue 24-25, 2006, Pages 5406-5422

  Brass, Sascha ^a   Chan, Nan Si ^a   Gerlach, Christof ^a   Luksch, Torsten ^a   Böttcher, Jark ^a   Diederich, Wibke E ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Aspartic proteases; Azacycles; Azepines; Privileged structures; RCM

Indexed keywords

ENZYME INHIBITION; ENZYMES; MOLECULAR STRUCTURE; SYNTHESIS (CHEMICAL);

ALLYLAMINES; ASPARTIC PROTEASE INHIBITORS; AZACYCLES; AZEPINES; PRIVILEGED STRUCTURES; RCM; RING-CLOSING METATHESIS;

OLEFINS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33751240084     PISSN: 0022328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jorganchem.2006.09.031     Document Type: Article

References (49)

1. For recent reviews on ring closing metathesis see:. Schuster M., and Blechert S. Angew. Chem., Int. Ed. 36 (1997) 2036-2056
2. Grubbs R.H., and Chang S. Tetrahedron 54 (1998) 4413-4450
3. Fürstner A. Top. Organomet. Chem. 1 (1998) 37-72
4. Fürstner A. Angew. Chem., Int. Ed. 39 (2000) 3012-3043
5. Trnka T.M., and Grubbs R.H. Acc. Chem. Res. 34 (2001) 18-29
6. Available from: .
7. For reviews see:. Phillips A.J., and Abell A.D. Aldrichim. Acta 32 (1999) 75-89
8. Nadin A. J. Chem. Soc., Perkin Trans. 1 (1998) 3493-3513
9. Mitchinson A., and Nadin A. J. Chem. Soc., Perkin Trans. 1 (1999) 2553-2581
10. Mitchinson A., and Nadin A. J. Chem. Soc., Perkin Trans. 1 (2000) 2862-2892
11. Felpin F.-X., and Lebreton J. Eur. J. Org. Chem. (2003) 3693-3712
12. Deiters A., and Martin S.F. Chem. Rev. 104 (2004) 2199-2238
13. Brass S., Gerber H.-D., Dörr S., and Diederich W.E. Tetrahedron 62 (2006) 1777-1786
14. Greenwood B., and Mutabingwa T. Nature 415 (2002) 670-672
15. Sachs J., and Malaney P. Nature 415 (2002) 680-685
16. Snow R.W., Craig M., Deichmann U., and Marsh K. Bull. World Health Organ. 77 (1999) 624-640
17. World Health Organisation/UNICEF The Africa Malaria report (2003) 1-112.
18. Laurent C., Bourgeois A., Mpoudi M., Butel C., Peeters M., Mpoudi-Ngole' E., and Delaporte E. Emerg. Infect. Dis. 10 (2004) 1953-1956
19. Francis S.E., Sullivan Jr. D.J., and Goldberg D.E. Annu. Rev. Microbiol. 51 (1997) 97-123
20. Coombs G.H., and Mottram J.C. Parasitology 114 Suppl. (1997) S61-S80
21. Leung D., Abbenante G., and Fairlie D.P. J. Med. Chem. 43 (2000) 305-341
22. Werbovetz K.A. Curr. Med. Chem. 7 (2000) 835-860
23. Rosenthal P.J. Emerg. Infect. Dis. 4 (1998) 49-57
24. Francis S.E., Gluzman I.Y., Oksman A., Knickerbocker A., Mueller R., Bryant M.L., Sherman D.R., Russell D.G., and Goldberg D.E. EMBO J. 13 (1994) 306-317
25. Banerjee R., Liu J., Beatty W., Pelosof L., Klemba M., and Goldberg D.E. Proc. Natl. Acad. Sci. USA 99 (2002) 990-995
26. Ersmark K., Feierberg I., Bjelic S., Hamelink E., Hackett F., Blackman M.J., Hulten J., Samuelsson B., Aqvist J., and Hallberg A. J. Med. Chem. 47 (2004) 110-122
27. Liu J., Gluzman I.Y., Drew M.E., and Goldberg D.E. J. Biol. Chem. 280 (2005) 1432-1437
28. De Clercq E. J. Med. Chem. 48 (2005) 1297-1313
29. Leung D., Abbenante G., and Fairlie D.P. J. Med. Chem. 43 (2000) 305-341
30. Rich D.H. J. Med. Chem. 28 (1985) 263-273
31. Cooper J.B. Current Drug Targets 3 (2002) 155-173
32. Specker E., Böttcher J., Brass S., Heine A., Lilie H., Schoop A., Müller G., Griebenow N., and Klebe G. ChemMedChem 1 (2006) 106-117
33. Specker E., Böttcher J., Lilie H., Heine A., Schoop A., Müller G., Griebenow N., and Klebe G. Angew. Chem., Int. Ed. 44 (2005) 3140-3144
34. Compound 13 has already been synthesized via a different sequence:. Khazaei A., Vaghei R.G., and Karkhanei E. Synth. Commun. 32 (2002) 2107-2113
35. Anzeveno P.B., Campbell J.A., and White W.L. Synth. Commun. 16 (1986) 387-392
36. Saimoto H., Nishio K., Yamamoto H., Shinoda M., Hiyama T., and Nozaki H. Bull. Chem. Soc. Jpn. 56 (1983) 3093-3098
37. Duettmann H., and Weyerstahl P. Chem. Ber. 112 (1979) 3480-3485
38. Maynard H.D., and Grubbs R.H. Tetrahedron Lett. 40 (1999) 4137-4140
39. For a representative procedure see:. Kirkland T.A., and Grubbs R.H. J. Org. Chem. 62 (1997) 7310-7318
40. Compound 21 has already been described in the literature:. Smith III A.B., Levenberg P.A., Jerris P.J., Scarborough R.M., and Wovkulich P.M. J. Am. Chem. Soc. 103 (1981) 1501-1513 the described method seems to be less convenient
41. Brandau S., Fröhlich R., and Hoppe D. Tetrahedron Lett. 46 (2005) 6709-6711
42. Scholl M., Ding S., Lee C.W., and Grubbs R.H. Org. Lett. 1 (1999) 953-956
43. Majumder U., Cox J.M., and Rainier J.D. Org. Lett. 5 (2003) 913-916
44. Chatterjee A.K., Toste F.D., Goldberg S.D., and Grubbs R.H. Pure Appl. Chem. 75 (2003) 421-425
45. Marhold M., Buer A., Hiemstra H., Maarseveen J.H.v., and Haufe G. Tetrahedron Lett. 45 (2004) 57-60
46. Taylor A., Brown D.P., Kadam S., Maus M., Kohlbrenner W.E., Weigl D., Turon M.C., and Katz L. Appl. Microbiol. Biotechnol. 37 (1992) 205-210
47. Toth M.V., and Marshall G.R. Int. J. Pept. Prot. Res. 36 (1990) 544-550
48. Weik S., Luksch T., Evers A., Böttcher J., Sotriffer C.A., Hasilik A., Löffler H.-G., Klebe G., and Rademann J. ChemMedChem 1 (2006) 445-457
49. Ahn Y.M., Yang K.-L., and Georg G.I. Org. Lett. 3 (2001) 1411-1413